1st Optimal Review: It Names Its Pharmacy and Almost Never Names a Peptide

What checking the pharmacy actually turns up

FDA issued a warning letter on March 31, 2023 to "Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy", reference MARCS-CMS 653740. ¹¹ A reader who takes 1st Optimal's disclosure and runs it through the warning-letter index will find it, and the temptation is to stop reading there.

Open the letter and three things change.

The inspection was of "Drug Depot, LLC dba APS Pharmacy, located at 34911 US Highway 19 N Ste 600, Palm Harbor, Florida" — a different facility, in a different state, from the Golden, Colorado pharmacy 1st Optimal names. The findings concern bulk drug substances used at that facility that were not the subject of a USP or NF monograph, were not components of FDA-approved drugs, and did not appear on the 503A bulks list.

And FDA's own warning-letter table records a close-out date of October 30, 2023 in its sixth column — the column that most people quoting these letters never open. A close-out means FDA has completed an evaluation and concluded the firm has addressed the violations.

So the honest report is: not 1st Optimal's letter; not about the facility 1st Optimal names; and closed out for nearly three years. That entire paragraph only exists because the company published a name. A provider that says "our partner pharmacies" gives a reader nothing to check and no way to be reassured either.

And then it will not tell you what the drug is

Now the other half, and it is the larger half.

1st Optimal's two page sitemaps list 213 URLs. All 213 were downloaded on August 9, 2026: 90,029,350 characters of published website.

Across all of it, these strings occur zero times: "BPC-157", "TB-500", "PT-141", "Ipamorelin", "retatrutide", "USP", "sterile", "sterility", "certificate of analysis", "potency", "purity", "503B".

Two peptide molecules are named. Both are in a single bullet on /mens-hormones/, and the bullet reads: "Peptide therapy (Sermorelin / CJC-1295): Peptides stimulate your own pituitary to produce more GH naturally, safer than direct GH with fewer side effects."

The words semaglutide and tirzepatide appear once each in the entire corpus, and not in a sentence — they are inside a link label reading "Related reading: semaglutide vs tirzepatide comparison", on /functionalhealthplans/weight-loss-copy/, a page whose slug ends in "-copy" and which is in the sitemap anyway.

Everything else is "peptides". The /peptides/ page sells four categories of them: "Fat Loss & Body Composition", "Injury & Training Recovery", "Growth Hormone & Muscle", "Performance & Longevity". Not one names a molecule.

This is not pedantry about labelling. A patient who cannot name their medication cannot look up its evidence, cannot check an interaction against anything else they take, cannot search for a side effect they are experiencing, and cannot tell an emergency physician what is in them. The disclosure at the bottom of the terms of service tells them who compounded it. It does not tell them what.

CJC-1295 and the one trial

Take the two molecules that are named, since they are the only two that can be checked.

Sermorelin. As of August 2026, a PubMed search filtered to the randomised-controlled-trial publication type returns 19 records, the newest published in 2005. ^{1 2} Every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None measures body composition in healthy adults.

CJC-1295. A ClinicalTrials.gov search for CJC-1295 as an intervention returns one study. Not one relevant study — one study, total. NCT00267527, sponsored by ConjuChem: "A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study to Evaluate the Efficacy and Safety of CJC 1295 Administered for 12 Weeks in HIV Infected Patients With HIV Associated Visceral Obesity." Enrolment 120. Listed completion, September 2006. Status: TERMINATED. ³

That is the entire registered clinical history of a molecule being sold in 2026 to healthy men to amplify body composition.

Now read 1st Optimal's sentence again with that in view. "Peptides stimulate your own pituitary to produce more GH naturally" — true, and the follow-up line, "[p]eptide therapy is not HGH", is a genuinely useful distinction that much of this market blurs deliberately. "Safer than direct GH with fewer side effects" is something else: a comparative safety claim, about two drugs, which no trial has tested. It is inferred from the mechanism. Mechanistic inference is how you generate a hypothesis, not how you establish that one drug is safer than another — which is the whole reason trials exist.

The claims with no molecule at all

The /peptides/ page makes four promises. Three of them have no referent.

"Injury & Training Recovery: Accelerates tendon, ligament, and muscle repair reducing downtime between hard training cycles and rehabilitating chronic injuries that resist standard treatment." Present tense, no hedge, no drug named.

There is no registry record to match against that, because there is nothing to search for. As a bound on the class the claim describes, the two molecules this market actually uses for tendon repair were searched on August 9, 2026. "BPC-157" returns three studies: a phase 1 safety and pharmacokinetics trial with status UNKNOWN and enrolment 42; a phase 2 hamstring-strain trial that is recruiting toward 120; and a completed 40-participant study of peptide gummies on inflammation markers, no phase assigned. ⁴ "TB-500" returns one: a phase 1/2 cardiovascular-biomarker study, recruiting, target 80. ⁵ No completed trial in that set measures tendon or ligament repair. Whatever molecule sits behind 1st Optimal's sentence, the sentence is ahead of the field. This is the recurring gap between what people report anecdotally about healing peptides and what has been trialled.

"Performance & Longevity: Peptides that support cardiovascular health, cognitive output, testosterone amplification, and cellular longevity used by high-performing men who want to extend their prime, not just manage decline." Four outcomes, one sentence, no molecule. Each would be a serious clinical programme if anyone had run it. And the last one is not merely unevidenced but unevidenceable on current data: no trial of any intervention has demonstrated an increase in human lifespan, because the follow-up does not exist.

"Fat Loss & Body Composition: Targets visceral fat and metabolic efficiency particularly effective when stacked weight loss protocols to produce superior body composition outcomes." Same shape. "Particularly effective" is a comparative efficacy claim about an unnamed drug in an unnamed combination.

The framing that holds the page together is the opening line: "Peptides are signaling molecules your body already produces. Therapy simply restores what's declined or fallen out of balance." That is true of some peptides and false of most of what this market sells — CJC-1295 is a modified GHRH fragment with a drug-affinity complex bolted on to extend its half-life; it is not something a body produces and it is not being restored. The framing makes an entire pharmacological category sound like topping up a vitamin.

The GLP-1 plan, and the price that is not there

The weight-loss plan is the one product with real evidence behind it, and it is sold at $99 a month as "Individualized GLP-1 Protocols" for "Personalized GLP-1 Weight Loss".

The class earns that. STEP 1 randomised 1,961 adults to once-weekly semaglutide or placebo. ^{6 7} SURMOUNT-1 randomised 2,539 to tirzepatide. ^{8 9} The plan page promises a protocol and a coach rather than a number, which is the correct posture.

But nothing on that page says which of the two drugs it is, and nothing on it says the preparation is compounded — the word "compounded" appears on exactly two of the 213 pages, and neither is a plan page. No compounded GLP-1 from any seller has been through a registered trial, which is the ordinary state of this market and is not the same thing as the trial drug, but a buyer cannot reach that thought without first being told what they are buying.

The pricing has the same shape. Every published figure is the membership: Peptides Care $109 per three months, Weight Loss Care $99 a month, Men's Hormone Care $169, Perimenopause $129, Menopause $239. The medication is billed separately and its price appears nowhere on the site — the only statement about it is an average "40% savings vs. retail MSRP on treatments", a percentage off a number that is also not given.

"We remove contaminants"

Which leaves the quality claim, and one pronoun in it.

From the FAQ: "Our Prescription Treatments are made-to-order, ensuring they're fresh and potent. With advanced purification processes, we remove contaminants, delivering the highest quality peptides every time."

1st Optimal compounds nothing. Its own clinical policy and FAQ describe a partner pharmacy that fills the prescription, applies the label and prints the dosing instructions. The purification processes, whatever they are, belong to Belmar. The sentence claims them in the first person.

And nothing documents them. Across 90,029,350 characters there is no standard cited, no laboratory named, no testing frequency, no tolerance, and no certificate of analysis for any lot. The words "USP", "sterile", "sterility", "certificate of analysis", "potency" and "purity" do not appear.

The peptides page's headline — "Lab-tested, physician-supervised and dosing unique to your needs" — reads at first glance as product testing. It is not. The labs are the patient's: 30-plus markers, DUTCH hormone panels, GI-MAP stool testing, IGF-1 used to titrate therapy. That is a serious diagnostic programme and 1st Optimal deserves credit for it. It is a measurement of the person, not of the drug, and those are two different documents entirely. The about page's "every treatment is pharmacy-grade" completes the picture: a phrase with no regulatory meaning at all, sitting where a standard should be.

One smaller thing, noted because it is checkable and because it suggests how the pages were assembled. /peptide-therapy-for-women/ carries an intake form headed "Schedule your gut health consultation", "designed for men experiencing" bloating, gas, the "Gut-Testosterone Link" and "Stubborn Belly Fat". The women's peptide page is collecting leads with the men's gut form.

What it adds up to

Set the two halves side by side, because the contrast is the review.

1st Optimal will tell you the name, street address, phone number and regulatory section of the pharmacy that makes your medicine. It will run thirty-plus markers before anyone prescribes anything, publish every membership tier, state what the membership includes, and decline to treat men who want testosterone purely for bodybuilding. Those are the marks of a company that has thought about being checkable.

And it will not tell you what drug it is going to give you. The most transparent supply-chain disclosure in this review sits at the bottom of a terms-of-service page, on a site that sells tendon repair, cognitive output, testosterone amplification and cellular longevity without naming a single molecule responsible for any of them.

The disclosure is real. There is just nothing to attach it to.